Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm.

Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal (2007) 2.03

Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol (2012) 1.17

Heme oxygenase-1 in inflammation and cardiovascular disease. Am J Cardiovasc Dis (2011) 1.10

Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Malar J (2003) 1.05

Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol (2010) 1.03

Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: role in therapeutic revascularization. Antioxid Redox Signal (2014) 0.98

Hemodynamic influences on abdominal aortic aneurysm disease: Application of biomechanics to aneurysm pathophysiology. Vascul Pharmacol (2010) 0.95

Genes and abdominal aortic aneurysm. Ann Vasc Surg (2010) 0.95

Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet (2009) 0.90

Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease. Arterioscler Thromb Vasc Biol (2014) 0.86

The association between heme oxygenase-1 gene promoter polymorphism and the outcomes of catheter ablation of atrial fibrillation. PLoS One (2013) 0.83

Heme Oxygenases in Cardiovascular Health and Disease. Physiol Rev (2016) 0.82

The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment. Front Cardiovasc Med (2015) 0.79

Heme Oxygenase-1 Expression Affects Murine Abdominal Aortic Aneurysm Progression. PLoS One (2016) 0.78

Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis. Oncotarget (2016) 0.75

Heme oxygenase-1 deficiency exacerbates angiotensin II-induced aortic aneurysm in mice. Oncotarget (2016) 0.75

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 8.20

The risk of recurrent venous thromboembolism in men and women. N Engl J Med (2004) 7.41

Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med (2006) 6.51

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01

Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J (2011) 4.47

Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med (2008) 3.87

Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med (2004) 3.63

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34

D-dimer levels and risk of recurrent venous thromboembolism. JAMA (2003) 3.30

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil (2005) 3.17

Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08

Does carotid stent cell design matter? Stroke (2008) 3.02

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97

Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90

Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88

Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation (2007) 2.80

Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention (2013) 2.48

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med (2004) 2.27

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA (2012) 2.22

Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis. Stroke (2005) 2.10

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J (2014) 2.10

Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev (2014) 2.08

Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci (2004) 2.08

Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions. Radiology (2004) 2.07

Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol (2002) 2.02

How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00

Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol (2009) 1.98

Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med (2004) 1.98

Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis (2005) 1.94

Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv (2009) 1.90

Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation (2005) 1.89

Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88

Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther (2003) 1.85

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J (2014) 1.81

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet (2011) 1.80

D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J (2007) 1.79

D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78

Renal artery PTA and stent implantation: immediate and late clinical and morphological outcome. Wien Klin Wochenschr (2002) 1.69

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69

In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67

Dental and periodontal status and risk for progression of carotid atherosclerosis: the inflammation and carotid artery risk for atherosclerosis study dental substudy. Stroke (2006) 1.65

Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology (2002) 1.65

Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesth Analg (2007) 1.65

Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J (2004) 1.64

Risk score for peri-interventional complications of carotid artery stenting. Stroke (2006) 1.63

High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62

Heme oxygenase and carbon monoxide initiate homeostatic signaling. J Mol Med (Berl) (2007) 1.60

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation (2009) 1.60

[The Club of Female Professors of the Medical University Vienna]. Wien Med Wochenschr (2009) 1.60

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2014) 1.59

Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost (2010) 1.58

Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2006) 1.58

To work in a hospital--a new risk factor for development of venous disease? Wien Klin Wochenschr (2003) 1.57

Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab (2013) 1.57

Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem (2007) 1.56

Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood (2012) 1.56

Chlamydia pneumoniae in carotid artery atherosclerosis: a comparison of its presence in atherosclerotic plaque, healthy vessels, and circulating leukocytes from the same individuals. Stroke (2002) 1.55